ClinicalTrials.gg
CompletedNCT06281795NANSAUpdated Jul 20, 2026

Neuromodulation of the Autonomic Nervous System in Athletes

An interventional study of tVNS in Efficacy, Self, Fatigue; Muscle, Heart and Fatigue, Mental, sponsored by Bakulev Scientific Center of Cardiovascular Surgery. Completed at 1 site in Russia. Open to participants aged 15 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Primary conditionMental FatigueRegistry: FatigueReclassifiedWhy we changed it
Registry
Fatigue — the first condition term the registry derived for this study.
ClinicalTrials.gg
Mental Fatigue
Why
  1. The study's listed conditions name Mental Fatigue, a narrower term within Fatigue.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bakulev Scientific Center of Cardiovascular Surgery · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
15 Years to 35 Years
Sex
All
01

Study summary

There are few studies in the literature that have evaluated the effects of using percutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery after physical exertion). It has been demonstrated that tVNS in athletes improved the rate of heart rate recovery, reduced lactic acid levels in blood plasma, reduced pain, reduced overtraining syndrome and fatigue levels.

Read the detailed description

Several studies have shown that transcutaneous vagus nerve stimulation (tVNS) potentially exhibits therapeutic effects similar to its invasive counterpart. tVNS is performed using surface electrodes and low-frequency electrical currents, targeting specific locations, most commonly the auricular branch of the vagus nerve or its cervical branch.

Stimulation of the auricular branch of the vagus nerve activates vagal sensory fibers, simulating sensory input to the brainstem and forming what is known as the auriculo-vagal afferent pathway. Since these fibers project directly to the nucleus of the solitary tract (also known as the solitary tract nucleus), which in turn has direct or indirect projections to nuclei that provide noradrenergic, endorphinergic, and serotonergic fibers in various parts of the brain, regulating systemic parameters of cardiovascular, respiratory, and immune functions, it can be expected that the body's response to stimulation of the auricular branch of the vagus nerve will be systemic.

With the onset of physical exercise, sympathetic activity in the body increases and reaches a plateau value after a certain period of maximum activity. After the end of physical exercise, suppressed parasympathetic activity begins to intensify, and the sympathetic system gradually returns to a resting state. After training, parasympathetic system activation continues for up to 48 hours. In certain types of training, when the frequency of anaerobic respiration increases during physical exertion, a decrease in parasympathetic reactivation may be observed.

In the literature, there are individual studies that have evaluated the effects of transcutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery processes after physical exertion). It has been demonstrated that tVNS in athletes improves heart rate recovery, reduces lactate levels in plasma, reduces pain sensations, decreases overtraining syndrome, and reduces fatigue levels.

The aim of this study is to: evaluate the influence of low-frequency electrical stimulation of the auricular branch of the vagus nerve on the functional reserve of the cardiovascular and respiratory systems in athletes during the post-training period, after high-intensity workouts.

02

Conditions studied

  • Efficacy, Self
  • Fatigue; Muscle, Heart
  • Fatigue, Mental
  • Fatigue; Combat

Browse trials for

Keywords

  • auricular stimulation
  • auricular vagus nerve stimulation
  • transcutaneous vagus nerve stimulation (tVNS)
  • vagus nerve stimulation (VNS)
  • heart rate
  • heart rate variability
  • power of high-frequency oscillations (HF)
  • power of low-frequency oscillations (LF)
  • LF/HF
  • index centralization (IC)
  • index of vegetative balance (IVB)
  • athletes
  • sport
  • maximum oxygen consumption (VO2max)
  • treadmill speed
  • anaerobic threshold of metabolism.
  • aerobic metabolism threshold of metabolism
03

In context

Mental Fatigue Reclassified

175 studies on the registry are indexed under Mental Fatigue; 55 are open to participants now.

This study's enrollment of 121 is above the median of 45 across 145 interventional studies indexed under Mental Fatigue.

Browse Mental Fatigue studies →

Lead sponsor

Bakulev Scientific Center of Cardiovascular Surgery is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Compared within Mental Fatigue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fatigue. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
15 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Professional athletes over the age of 15 and under the age of 35;
  • Cyclic sports (swimming, modern pentathlon, athletics, triathlon);
  • Difficult coordination sports (dance sports, rhythmic gymnastics);
  • Sports category: no lower than candidate for master of sports;
  • Voluntary .

Exclusion criteria

Exclusion Criteria:

  • Atypical and unrelated to physical exertion changes on the (T wave inversion, st-segment depression, pathological Q waves, signs of left atrial enlargement, signs of right ventricular hypertrophy, ventricular pre-excitation, complete right or left bundle branch block, prolonged or shortened Q-T interval, Brugada-like early repolarization);
  • Heart rhythm and conduction disorders (frequent ventricular and supraventricular extrasystoles, first-degree atrioventricular block (P-Q > 0.21 s, not shortened during hyperventilation or physical exertion), second or third degree);
  • Expressed sinus bradycardia with resting heart rate \< 40 bpm;
  • Taking glucocorticosteroids in the last 1 month;
  • Taking any antiarrhythmic drugs, including beta-blockers.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Active comparator
    Active tVNS

    Active stimulation will be carried out using the tVNS device with an ear clip attached to the tragus of the left ear at a frequency of 20 Hz, 200 μs at a current slightly below the discomfort threshold. The device's operating mode is active therapeutic.

    Device: tVNS

  • Sham comparator
    Sham tVNS

    Fictitious stimulation will be carried out using the tVNS device with an ear clip attached to the tragus of the left ear at a frequency of 20 Hz, 200 μs at a current slightly below the discomfort threshold. The device's operating mode is research mode.

    Device: tVNS

Interventions

  • DevicetVNS

    tVNS will be performed daily after workouts for 60 minutes over a period of 8 weeks.

06

What researchers measure

Primary outcomes

  1. Dynamics of maximum oxygen consumption (VO2max).

    During a cardiorespiratory exercise test, the level of VO2max (ml/min/kg) is assessed.

    Time frame: The level of VO2max is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and fictitious stimulation groups.

  2. The dynamics of the treadmill speed at the level of the anaerobic threshold of metabolism.

    During the cardiorespiratory exercise test, the treadmill speed (km/h) is estimated at the level of the anaerobic metabolic threshold.

    Time frame: Treadmill speed is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and dummy stimulation groups.

Secondary outcomes

  1. Dynamics of the treadmill speed at the level of the aerobic metabolism threshold of metabolism.

    During the cardiorespiratory exercise test, the treadmill speed (km/h) is estimated at the level of the aerobic metabolic threshold.

    Time frame: Treadmill speed is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and dummy stimulation groups.

  2. The dynamics of the heart rate (HR) at the level of the anaerobic threshold of metabolism.

    During the cardiorespiratory exercise test, the HR is estimated at the level of the anaerobic metabolic threshold.

    Time frame: HR is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and dummy stimulation groups.

  3. The dynamics of the heart rate (HR) at the level of the aerobic threshold of metabolism.

    During the cardiorespiratory exercise test, the HR is estimated at the level of the aerobic metabolic threshold.

    Time frame: HR is estimated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and dummy stimulation groups.

  4. The dynamics of RMSSD.

    During the time analysis of heart rate variability, the RMSSD parameter is estimated.

    Time frame: This parameter is evaluated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the groups of active and fictitious stimulation.

  5. HF dynamics

    During the spectral analysis of heart rate variability, the HF (high frequency) parameter is estimated.

    Time frame: This parameter is evaluated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the groups of active and fictitious stimulation.

  6. Dynamics of the LF/HF ratio.

    The LF/HF ratio is estimated during the spectral analysis of heart rate variability.

    Time frame: This LF/HF ratio is evaluated at the beginning of the study (initially) and at the end of the study (after 8 weeks) in the active and fictitious stimulation groups.

07

Study locations

1 site
  • Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPION
    Krasnodar, Russia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Mar 2026, 23 months.

Of 81 non-industry interventional studies with no phase under Mental Fatigue, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 94 studies reached it within 8 months; a quarter within 3 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Feb 28, 2024
StartActual
Apr 1, 2024
Primary completionActual
Mar 1, 2026
CompletionActual
Mar 31, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06281795
Lead sponsor
Bakulev Scientific Center of Cardiovascular Surgery
Collaborators
Foundation for the Support of Physical Culture and Sports BECOME A CHAMPION, Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPION
Responsible party
Vladimir A Shvartz, MD (MD, DM, Professor, Bakulev Scientific Center of Cardiovascular Surgery) — Principal investigator
First posted
Feb 28, 2024
Start date
Apr 1, 2024
Primary completion
Mar 1, 2026
Completion
Mar 31, 2026
Last update
Jul 20, 2026

Study contacts

Vasiliy Danilov
study chair · Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPION

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion